We focus on high-value molecular diagnostic tests that can help inform the treatment decisions physicians make every day. You can learn more about these tests or order sample collection kits by clicking on the links below.

Molecular tests that identify genetic alterations and/or changes in gene expression profiles associated with thyroid cancer.

Request Test Kits

Specimen collection kits may be ordered by physicians or other authorized health care professionals.

Kits include all that is needed for sample collection and are complimentarily provided.

To request a kit, please call 844-405-9655

Molecular diagnostic test that aids in diagnosing and classifying the risk of progression to cancer in pancreatic cysts.


Interpace Diagnostics provides full product commercialization and is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management.


To improve patient care through personalized medicine and molecular diagnostic tests supported by rigorous science

By combining the long and successful history of PDI, Inc. with a depth of experience specific to the diagnostics and reimbursement environments, Interpace Diagnostics has:

  • The ability to tap into the power of PDI's commercial expertise and infrastructure

  • Expertise in health care provider promotion and product commercialization

  • An understanding of how to bring tests with high clinical value and utility to market

  • Acquired Asurgen's thyroid and pancreas assets

  • A leader in molecular diagnostics as a member of PDI Inc's Board of Directors

  • Acquired CLIA-certified and CAP-accredited commercial laboratory in New Haven, CT

  • Acquired Redpath Integrated Pathology, including their CLIA- and CAP-accredited commercial laboratory

Our unique approach allows molecular diagnostics companies the ability to bring their products to market in a more cost-effective and efficient, as well as faster, manner.



New Haven

  • Located near Yale University
  • Medical Director Henry Rinder, MD
  • Access to top scientific talent
  • miRNA and endocrine focus
  • NextGen Sequencing
  • CLIA-certified



  • Located near University of Pittsburgh
  • Chief Scientific Officer Syd Finkelstein, MD
  • Access to top scientific talent
  • Complex molecular testing capabilities, GI focused
  • CLIA-certified, CAP-accredited facility



Interpace Diagnostics
Morris Corporate Center 1, Building A
300 Interpace Parkway
Parsippany, NJ 07054


You can also learn more about our novel approach and the depth of support we can offer you to commercialize your products by contacting:


SVP Commercial Services, Interpace Diagnostics LLC


Greg Richard, Sr. Vice President of PDI, Inc. and SVP of Commercial Services at Interpace Diagnostics, has been in the healthcare business for over 25 years in various industries including managed care, biotech pharmaceuticals, CRO services, and diagnostics. He started his career in sales at Aetna and moved to Genentech as the Director of Managed Care. He transitioned in to the diagnostics industry as the Vice President of Managed Care for Quest Diagnostics and served in this role for 8 years. Greg also led the international clinical trials sales team while at Quest. Following his tenure at Quest, Greg worked for several privately held companies including CRO’s, molecular diagnostics, and anatomic pathology services providers. He also served as the Sr. Vice President of Sales for the Northeast Division of LabCorp. Greg is a certified Six Sigma Green Belt and frequent speaker at healthcare industry conferences such as the G2 Lab Institute and the NextGen Dx Summit.



PDI Investor Relations

Nancy, a veteran in the biopharmaceutical industry, joined PDI in November 2008 as Chief Executive Officer and a member of the company’s Board of Directors. Ms. Lurker has more than 25 years of experience in pharmaceutical sales, marketing, and commercial operations. Prior to joining PDI, she was Senior Vice President and Chief Marketing Officer for Novartis Pharmaceuticals Corporation (the US subsidiary of Novartis AG), where she oversaw a product portfolio in multiple therapeutic areas representing multi-billion dollars in annual sales. Ms. Lurker was also President and CEO of ImpactRx, Group Vice President-Global Primary Care Products for Pharmacia Corporation, and a member of Pharmacia’s US Executive Management Committee. She began her career at Bristol Myers Squibb, where she quickly rose from Senior Sales Representative to Senior Director of Worldwide Cardiovascular Franchise Management during her 14-year tenure. Ms. Lurker graduated magna cum laude with a BS in biology from Seattle Pacific University, and holds an MBA from the University of Evansville (Evansville, IN).

Interpace Diagnostics, the molecule logo, and Guiding Treatment. Delivering Innovation. are trademarks of Interpace Diagnostics, LLC.
©2015 Interpace Diagnostics, LLC. All rights reserved.